Harvard Bioscience Inc (HBIO)

Currency in USD
6.670
+0.500(+8.10%)
Closed·
6.730+0.060(+0.90%)
·
Unusual trading volume
HBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.0796.700
52 wk Range
3.7559.400
Key Statistics
Prev. Close
6.17
Open
6.12
Day's Range
6.079-6.7
52 wk Range
3.755-9.4
Volume
51.93K
Average Volume (3m)
19.82K
1-Year Change
36.2893%
Book Value / Share
1.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.500
Upside
+12.44%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Harvard Bioscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.500
(+12.44% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy7.50+12.44%6.00MaintainAug 12, 2026
Benchmark
Buy6.00-10.04%0.60MaintainMar 16, 2026
Benchmark
Buy0.60-91.00%2.00MaintainMar 13, 2026
Benchmark
Buy2.00-70.01%3.00MaintainSep 10, 2025

Harvard Bioscience Inc Earnings Call Summary for Q2/2026

  • Harvard Bioscience Q2 revenue rose 11% YoY to $22.7M, beating estimates of $21.9M; adjusted EPS loss of $0.14 topped forecast of $0.38 loss.
  • Company raised FY 2026 revenue growth guidance to 3-5% from 2-4%; Q3 revenue expected at $21.0-22.6M, implying 6% YoY growth at midpoint.
  • Recurring revenue reached 55% of H1 sales, nearing 60% target; Americas grew 13%, APAC 24%, and China surged 29% YoY in the quarter.
  • Project Viking manufacturing consolidation remains on track, expected to deliver $3M in cost savings in 2027 and $4M annually thereafter.
  • Stock rose 0.16% to $6.40 premarket; adjusted gross margin guidance trimmed to 57-59% from 58-60% due to product mix and China demand shifts.
Last Updated: 2026-08-11, 08:50 a/m
Read Full Transcript

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-0.14 / -0.38
Revenue / Forecast
22.73M / 21.9M
EPS Revisions
Last 90 days

HBIO Income Statement

Compare HBIO to Peers and Sector

Metrics to compare
HBIO
Peers
Sector
Relationship
P/E Ratio
−2.9x6.8x−0.4x
PEG Ratio
−0.030.000.00
Price/Book
4.1x1.1x2.6x
Price / LTM Sales
0.3x2.3x3.1x
Upside (Analyst Target)
14.0%45.5%48.4%
Fair Value Upside
Unlock1.9%6.5%Unlock

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
277.33K6.15%1.71M
Other Institutional Investors
2.02M44.75%12.45M
Public Companies & Retail Investors
2.21M49.11%13.67M
Total
4.51M100.00%27.83M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
AMH Equity, Ltd.7.54%340,1602,099
Leviticus Partners LP7.54%340,1602,099

People Also Watch

0.8824
ONCO
-1.03%
3.390
IPW
-2.02%
2.7400
NEXR
-3.18%
3.710
FULC
-0.27%
1.00
CAST
-19.51%

FAQ

What Is the Harvard Bioscience (HBIO) Stock Price Today?

The Harvard Bioscience stock price today is 6.670 USD.

What Stock Exchange Does Harvard Bioscience Trade On?

Harvard Bioscience is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Harvard Bioscience?

The stock symbol for Harvard Bioscience is "HBIO."

What Is the Harvard Bioscience Market Cap?

As of today, Harvard Bioscience market cap is 30.080M USD.

What Is Harvard Bioscience's Earnings Per Share (TTM)?

The Harvard Bioscience EPS (TTM) is -2.349.

When Is the Next Harvard Bioscience Earnings Date?

Harvard Bioscience will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is HBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Harvard Bioscience Stock Split?

Harvard Bioscience has split 1 times.

How Many Employees Does Harvard Bioscience Have?

Harvard Bioscience has 328 employees.

What is the current trading status of Harvard Bioscience (HBIO)?

As of Aug 14, 2026, Harvard Bioscience (HBIO) is trading at a price of 6.670 USD, with a previous close of 6.170 USD. The stock has fluctuated within a day range of 6.079 USD to 6.700 USD, while its 52-week range spans from 3.755 USD to 9.400 USD.

What Is Harvard Bioscience (HBIO) Price Target According to Analysts?

The average 12-month price target for Harvard Bioscience is 7.500 USD, with a high estimate of 7.5 USD and a low estimate of 7.5 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +12.44% Upside potential.

What Is the HBIO Premarket Price?

HBIO's last pre-market stock price is 6.390 USD. The pre-market share volume is 20.000, and the stock has decreased by 0.220, or 3.570%.

What Is the HBIO After Hours Price?

HBIO's last after hours stock price is 6.730 USD, the stock has decreased by 0.060, or 0.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.